GlassScriptPhysician profile
Shani C Kotadia
NPI 1619256807
$2,104.07
in general payments reported to CMS, 2019-2025
25 companies · $461 in 2025
The $461 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $214 · 2020: $29.97 · 2021: $366 · 2022: $552 · 2023: $178 · 2024: $303 · 2025: $461.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $937 · Education: $5.32.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $936.72 |
| Education | $5.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $513.92 | 2019-2025 | Farxiga, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $227.03 | 2022-2025 | |
| Novo Nordisk INC | $158.58 | 2022-2024 | Rivfloza, Ozempic |
| Vantive US Healthcare LLC | $149.33 | 2025 | Renal - Pd |
| Otsuka America Pharmaceutical, INC. | $146.38 | 2019-2024 | Jynarque |
| Horizon Therapeutics Plc | $129.86 | 2020-2023 | Krystexxa |
| Amgen INC. | $124.78 | 2019-2025 | Krystexxa, Tavneos |
| Glaxosmithkline, LLC. | $113.78 | 2021-2024 | Jesduvroq, Benlysta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.85 | 2024 | Jardiance |
| Opko Pharmaceuticals, LLC | $57.00 | 2019-2021 | |
| Ardelyx, INC. | $49.22 | 2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $44.64 | 2022-2025 | Tarpeyo |
| Vifor Pharma, INC. | $43.37 | 2019-2023 | Veltassa |
| Apellis Pharmaceuticals, INC. | $34.42 | 2025 | Empaveli |
| Novartis Pharmaceuticals Corporation | $33.23 | 2021-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fresenius USA Marketing, INC. | $32.80 | 2021-2022 | |
| Alnylam Pharmaceuticals INC. | $23.82 | 2025 | Givlaari |
| Travere Therapeutics, INC. | $23.65 | 2024 | |
| Akebia Therapeutics INC | $23.54 | 2021 | |
| Cormedix INC. | $21.63 | 2025 | Defencath |
| Tanabe Pharma America, INC. | $20.99 | 2025 | Radicava |
| Chiesi USA, INC. | $20.98 | 2021 | |
| Alexion Pharmaceuticals, INC. | $18.45 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.56 | 2019 | |
| Janssen Pharmaceuticals, INC | $13.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shani Kotadia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.